For research and educational purposes only. Not intended for human consumption.
GLP3-R
Extensively Studied- •TRIUMPH-4: 28.7-29% weight loss!
- •Highest ever for any obesity drug
- •NDA submission expected 2026
- •82% liver fat reduction in MASLD
Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes
Overview
What is GLP3-R?
GLP3-R (LY3437943) is a novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase III TRIUMPH-4 trial (2025) achieved up to 28.7-29% weight loss at 68 weeks with 9-12mg doses - the highest recorded for any obesity medication. Eli Lilly plans NDA submission after summer 2026 data readouts, with potential approval late 2026/early 2027. Analysts forecast $15.6 billion sales by 2031.
Key Benefits
Triple hormone receptor activation provides superior weight loss (up to 29% at 12mg) vs dual agonists like glp2-t. Phase 2 data showed 24% average loss at 48 weeks. Improved glycemic control, pain reduction (76% in OA patients), and enhanced metabolic benefits. First new obesity drug class in ~20 years.
Mechanism of Action
Activates GLP-1 for appetite suppression/satiety, GIP for enhanced insulin sensitivity and glucose control, and glucagon for increased energy expenditure and hepatic fat oxidation. This triple mechanism outperforms single and dual agonists.
Molecular Information
Pharmacokinetics
Research Indications
Superior Weight Reduction
Clinical trials demonstrate 17.5% at 24 weeks and 24.2% at 48 weeks - highest recorded for any obesity medication in development.
Sustained Weight Management
Continuous weight loss throughout trials with no plateau reached at 48 weeks.
Triple Mechanism Obesity Treatment
Addresses obesity through appetite suppression, increased energy expenditure, and improved metabolic efficiency.
Research Protocols
Disclaimer: GLP3-R is in Phase III trials and not yet FDA approved. These protocols are based on clinical trial data. Consult a healthcare provider.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Conservative Starting (Week 1-4) | 0.5mg weekly | Once weekly | Subcutaneous |
| Low Maintenance (Week 4-8) | 1mg weekly | Once weekly | Subcutaneous |
| Standard Escalation (Week 8-12) | 2mg weekly | Once weekly | Subcutaneous |
| Moderate Weight Loss (Week 12-16) | 4mg weekly | Once weekly | Subcutaneous |
| Advanced Weight Loss (Week 16-20) | 8mg weekly | Once weekly | Subcutaneous |
| Maximum Efficacy (Week 20+) | 12mg weekly | Once weekly | Subcutaneous |
Timing: Administer on the same day each week for consistent hormone regulation. Can be taken with or without food.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Remove vial from refrigeration and allow to reach room temperature (15-20 minutes)
Clean vial top with alcohol swab and allow to air dry
Add calculated amount of bacteriostatic water slowly down the side of the vial
Gently swirl in circular motions - DO NOT shake vigorously
Allow to fully dissolve (may take 2-3 minutes) - solution should be clear and colorless
Store reconstituted solution in refrigerator (2-8°C) and use within 28 days
Rotate injection sites weekly to prevent lipodystrophy
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Pharmaceutical-Grade White Powder
Lyophilized GLP3-R appears as white to off-white powder with uniform texture.
Proper Cold Chain Maintenance
Reconstituted solution requires consistent refrigeration at 2-8°C.
Clear Reconstituted Solution
Properly reconstituted forms a clear, colorless solution without particles.
Source Verification Critical
Due to investigational status, verify pharmaceutical-grade sourcing.
Rapid Tolerance or Effectiveness Loss
Genuine GLP3-R maintains efficacy; rapid tolerance suggests degraded product.
Unusual Side Effect Profile
Effects different from expected GI-predominant profile may indicate counterfeit.
What to Expect
- •Week 1-2: Initial appetite suppression and mild GI effects
- •Week 2-4: Noticeable reduction in food cravings, early weight loss (2-5%)
- •Week 4-8: Significant appetite control and steady weight loss (5-10%)
- •Week 8-16: Substantial weight reduction (10-18%)
- •Week 16-24: Major weight loss milestone (15-22%)
- •Week 24-48: Maximum clinical efficacy (20-24.2%)
Side Effects & Safety
Side Effects
- •Most common side effects are gastrointestinal (nausea 43%, diarrhea 33% at 12mg)
- •NEW SIGNAL (Dec 2025): Dysesthesia reported in 8.8-20.9% of participants at 9-12mg doses
- •Conservative start at 0.5mg weekly minimizes GI side effects
- •Phase III discontinuation rates: 12.2% (9mg) and 18.2% (12mg)
- •Monitor for signs of pancreatitis - discontinue immediately if suspected
- •Heart rate increases common, especially in first 24 weeks
- •Contraindicated with history of medullary thyroid carcinoma or MEN2 syndrome
When to Stop
- •Signs of pancreatitis
- •Severe GI symptoms
- •Heart rate abnormalities
- •Signs of thyroid problems
- •As directed by healthcare provider
References
5 StudiesPhase III TRIUMPH-4 Trial (2025)
Human | 9-12mg weekly | 68 weeks | Obesity + OA | 28.7-29% weight loss at highest doses
First successful Phase III trial achieved up to 29% weight loss with 75.8% pain reduction and improved function in patients with obesity and knee osteoarthritis. Adverse event discontinuation rates: 12.2% (9mg), 18.2% (12mg) vs 4% placebo.
TRIUMPH-1 Trial (2023-2026)
Human | ~2,300 patients | Obesity/overweight | Primary completion May 2026
Major Phase 3 trial in obesity/overweight patients. Topline data expected summer 2026 to support NDA submission.
TRIUMPH-2 Trial (2023-2026)
Human | ~1,000 T2DM patients | ~89 weeks | T2D with obesity, some with sleep apnea
Phase 3 trial in Type 2 diabetes patients with obesity, completion due May 2026.
Quick Start Guide
Research Disclaimer
GLP3-R is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving GLP3-R must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of GLP3-R for any purpose. Consult qualified professionals for any research applications.